Study on the treatment strategy of combination of osimertinib and crizotinib

Osimertinib and crizotinib, as two targeted drugs that have attracted much attention in the field of lung cancer treatment, each have unique efficacy and advantages.

Osimertinib, as a third-generation EGFR inhibitor, has been proven to have significant efficacy in EGFR mutation-positive non-small cell lung cancer. It can efficiently and specifically inhibit the abnormal activation of the EGFR signaling pathway, thereby blocking the growth of tumor cells. Crizotinib is a multi-target targeted therapy drug that has inhibitory effects on multiple targets such as MET, ALK and ROS1, especially in ALK-positive non-small cell lung cancer.

Considering the different mechanisms and targets of osimertinib and crizotinib, their combination may produce better therapeutic effects. This combination strategy is expected to achieve simultaneous inhibition of multiple key signaling pathways, thereby more comprehensively blocking the proliferation and spread of tumor cells.

However, combination therapy is not a simple drug stack. In practical applications, it is necessary to fully consider the pharmacokinetic properties, dose ratio, treatment timing and other factors of the two drugs to ensure maximum efficacy and reduce potential risks. In addition, individual differences between different patients, such as gene mutation status, tumor microenvironment, etc., may also affect the effect of combination therapy.

Currently, clinical studies on the combination of osimertinib and crizotinib are gradually being carried out. These studies will provide us with more information about the effectiveness, safety and optimal medication regimen of combination strategies. At the same time, with the deepening of the concept of precision medicine, this combination treatment strategy is expected to be more personalized and optimized according to the specific conditions of patients in the future.